drugset / Trial / NCT02822547
Study on Treatment of Pegylated Interferon Alfa 2a(Pegasys®) in the Korean Chronic Hepatitis B(CHB) Adults
NaSingle-groupOpen-labelTreatment
Summary
Patients will receive Peginterferon alfa-2a according to the standard medical practice but the observation period is 12 weeks
Timeline
- Start
- 2015-03
- Primary completion
- 2016-09
- Completion
- 2016-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Peginterferon alfa-2a | Protein / enzyme biologic | — | — |